Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study

by Bible, K.C., Suman, V.J., Molina, J.R., Smallridge, R.C., Maples, W.J., Menefee, M.E., Rubin, J., Sideras, K., Morris, J.C., McIver, B., Burton, J.K., Webster, K.P., Bieber, C., Traynor, A.M., Flynn, P.J., Goh, B.C., Tang, H., Ivy, S.P., Erlichman, C.
Published 2016

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H

by Bible, K.C., Suman, V.J., Molina, J.R., Smallridge, R.C., Maples, W.J., Menefee, M.E., Rubin, J., Karlin, N., Sideras, K., Morris III, J.C., McIver, B., Hay, I., Fatourechi, V., Burton, J.K., Webster, K.P., Bieber, C., Traynor, A.M., Flynn, P.J., Goh, B.C., Isham, C.R., Harris, P., Erlichman, C.
Published 2016